Pacritinib
- Generic Name
- Pacritinib
- Brand Names
- Vonjo
- Drug Type
- Small Molecule
- Chemical Formula
- C28H32N4O3
- CAS Number
- 937272-79-2
- Unique Ingredient Identifier
- G22N65IL3O
- Background
Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. While some patients may remain asymptomatic, typical symptoms of MF arise from abnormali...
- Indication
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10/L.
...
- Associated Conditions
- High-Risk Secondary Myelofibrosis, High risk Primary Myelofibrosis (PMF), Intermediate risk Primary Myelofibrosis (PMF), Intermediate risk Secondary Myelofibrosis
- Associated Therapies
- -
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT06675123
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT06538181
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 44
- Registration Number
- NCT06516887
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06414681
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 160
- Registration Number
- NCT06303193
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06218628
- Locations
- 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
Pacritinib in CMML
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Douglas Tremblay
- Target Recruit Count
- 26
- Registration Number
- NCT06159491
- Locations
- 🇺🇸
The Mount Sinai Hospital, New York, New York, United States
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT06052618
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 118
- Registration Number
- NCT05980806
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇧🇪UZ Gent, Gent, Belgium
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT05531786
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.